Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Contraception

Therapeutic area intelligence for Contraception with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 8
Catalysts: 0
Companies: 3

Companies

AstraZeneca →

competing pharma companies →

Assets

Levonorgestrel →

Recent signals(8)

ClinicalJuly 29, 2026

AstraZeneca's Study on AZD6234 and AZD9550 Impact on Oral Contraceptive Pharmacokinetics

AstraZeneca is conducting a study to evaluate the pharmacokinetics of ethinyl estradiol/levonorgestrel when administered with AZD6234 and AZD9550.

RegulatoryJuly 23, 2026

FDA Approval Update for Norethindrone Acetate and Ethinyl Estradiol

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for a combination product containing Norethindrone Acetate and Ethinyl Estradiol.

RegulatoryJuly 21, 2026

FDA Accepts Supplement for Implanon by Organon

The FDA has accepted a supplemental application for Implanon, a contraceptive implant containing etonogestrel.

StrategyJuly 13, 2026

Study on Genetic Factors Influencing Emergency Contraceptive Efficacy

A study is investigating genetic differences that may affect the efficacy of oral emergency contraception.

RegulatoryJuly 8, 2026

FDA Grants AP Status for Introvale (ANDA079064) by Xiromed

The FDA has granted Abbreviated Approval (AP) status for Introvale, a contraceptive containing Ethinyl Estradiol and Levonorgestrel.

RegulatoryJuly 1, 2026

FDA Grants AP Status for Levonorgestrel and Ethinyl Estradiol ANDA202970

The FDA has granted Abbreviated Approval (AP) status for ANDA202970, a combination of Levonorgestrel and Ethinyl Estradiol.

RegulatoryJune 23, 2026

FDA Grants AP Status for Levonorgestrel and Ethinyl Estradiol ANDA200492

The FDA has granted an Abbreviated Approval (AP) status for ANDA200492, a combination of Levonorgestrel and Ethinyl Estradiol.

CompetitiveJune 23, 2026

Lupin's ANDA091440 for Levonorgestrel and Ethinyl Estradiol Receives AP Status

Lupin Ltd's ANDA091440 for a combination of Levonorgestrel and Ethinyl Estradiol has received an Abbreviated Approval (AP) status.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.